Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 52
Summary
- Conditions
- Lymphoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02974647
- Collaborators
- Cornell University
- Dana-Farber Cancer Institute
- Investigators
- Principal Investigator: Alison Moskowitz, MD Memorial Sloan Kettering Cancer Center
Get Well Soon